A cortisol-targeting antidepressant, Xanamem, has shown significant improvement in depression rates, peaking four weeks post-treatment. It selectively inhibits an enzyme that reduces cortisol in the brain without affecting overall cortisol levels. Despite cognitive improvements not correlating with mood enhancement, the drug offers a new avenue for treatment-resistant depression and Alzheimer’s research.













